NEWYou can now listen to Fox News articles! GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — were originally intended to treat type 2 diabetes and obesity. But in recent months, studies have shown that these...
